Associated Papers
Molecular Landscape of Metastatic Lung Adenocarcinoma in Bulgarian Patients-A Prospective Study.
Dimitrov G et al.
International Journal of Molecular Sciences, 2025
Progress on the development of prediction tools for detecting disease causing mutations in proteins.
Gromiha MM et al.
Computers in Biology and Medicine, 2025
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
A Challenging Correlation between Tumor Cellularity and Somatic Variant Allele Fraction in Lung and Colorectal Cancers-Specimens of Low Tumor Percentage Should Be Analyzed with Caution.
Zarabi SK et al.
Biomolecules, 2024
Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre.
Mosteiro M et al.
Esmo Open, 2023
EGFR Mutation Detection in Brazilian Patients With Non-Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing.
Montella T et al.
Jco Global Oncology, 2023
Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma.
Casula M et al.
International Journal of Molecular Sciences, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory.
Bhai P et al.
Frontiers in Oncology, 2023
Targeted Next-Generation Sequencing-Based Multiple Gene Mutation Profiling of Patients with Rectal Adenocarcinoma Receiving or Not Receiving Neoadjuvant Chemoradiotherapy.
Chang YK et al.
International Journal of Molecular Sciences, 2022
Somatic targeted mutation profiling of colorectal cancer precursor lesions.
Dos Santos W et al.
Bmc Medical Genomics, 2022
Ultrasensitive analysis of genetic instability related to chemical exposure.
Domoradzki T et al.
Journal of Applied Genetics, 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Winter H et al.
Cancers, 2019
Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer.
Xing P et al.
Journal of Cellular and Molecular Medicine, 2019
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing.
Kohsaka S et al.
Future Oncology (london, England), 2019
Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.
Vikova V et al.
Theranostics, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Investigating mutation-specific biological activities of small molecules using quantitative structure-activity relationship for epidermal growth factor receptor in cancer.
Anoosha P et al.
Mutation Research, 2017
A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.
Kohsaka S et al.
Science Translational Medicine, 2017
Clinical mutational profiling of 1006 lung cancers by next generation sequencing.
Illei PB et al.
Oncotarget, 2017
Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.
Li SD et al.
Genome Medicine, 2017
Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.
Alvarez-Cubero MJ et al.
Molecular Diagnosis & Therapy, 2017
The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
Tseng JS et al.
Oncotarget, 2016
Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.
Kaderbhai CG et al.
Oncotarget, 2016
Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer.
Anoosha P et al.
Mutation Research, 2015
Structural Stability and Flexibility Direct the Selection of Activating Mutations in Epidermal Growth Factor Receptor Kinase.
Paladino A et al.
Journal of Chemical Information and Modeling, 2015
Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan.
Hsu KH et al.
Plos One, 2015
Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa).
Fu M et al.
Virchows Archiv : an International Journal of Pathology, 2014
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.
Okamoto I et al.
Oncotarget, 2014
Lack of mutations in protein tyrosine kinase domain coding exons 19 and 21 of the EGFR gene in oral squamous cell carcinomas.
Mehta DT et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2014
Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
Tseng JS et al.
Plos One, 2014
Differential strand separation at critical temperature: a minimally disruptive enrichment method for low-abundance unknown DNA mutations.
Guha M et al.
Nucleic Acids Research, 2013
Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities.
Pommier SJ et al.
Annals of Surgical Oncology, 2012
Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.
Peraldo-Neia C et al.
Bmc Cancer, 2011
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.
Simonetti S et al.
Journal of Translational Medicine, 2010
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
Bronte G et al.
Cancer Treatment Reviews, 2010
Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
Wong KK
Lung Cancer (amsterdam, Netherlands), 2008
Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation.
Miyazawa H et al.
Cancer Science, 2008
Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro.
Puyo S et al.
Molecular Diagnosis & Therapy, 2008
Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.
Chen Z et al.
Plos One, 2008
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.
Liu W et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2007
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Ikediobi ON et al.
Molecular Cancer Therapeutics, 2006
[Mutations in the epidermal growth factor receptor: structure and biological function in human tumors].
Pedersen MW et al.
Ugeskrift for Laeger, 2006